Published April 2021 | Version v1
Journal article Metadata-only

Cost-Effectiveness Analysis of Stereotactic Ablative Radiation Therapy in Patients With Oligometastatic Cancer

Creators

  • 1. Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla (United States)

Description

The Stereotactic Ablative Radiation therapy for Comprehensive Treatment of Oligometastatic Tumors phase 2 randomized clinical trial found that stereotactic ablative radiation therapy (SABR) improved outcomes among cancer patients with oligometastatic disease. Yet, the cost of SABR along with the large number of patients with oligometastatic disease raises the important question of value. This study sought to evaluate the cost-effectiveness of the addition of SABR compared with standard therapy alone among cancer patients with oligometastatic disease.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2020.09.045

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2020.09.045;
PII
S0360301620343479;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
109
Journal Issue
5
Journal Page Range
p. 1185-1194
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
53124541
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CLINICAL TRIALS; COST EFFECTIVENESS ANALYSIS; NEOPLASMS; PATIENTS; RADIOTHERAPY
Descriptors DEC
DISEASES; ECONOMIC ANALYSIS; ECONOMICS; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; TESTING; THERAPY

Optional Information

Copyright
Copyright (c) 2020 Elsevier Inc. All rights reserved.